Skip to main content
QMSQMS
QMS
  • Welcome to your QMS
  • Quality Manual
  • Procedures
  • Records
  • Legit.Health Plus Version 1.1.0.0
    • Index of Technical Documentation or Product File
    • Summary of Technical Documentation (STED)
    • Description and specifications
    • R-TF-001-007 Declaration of conformity
    • GSPR
    • Artificial Intelligence
      • R-TF-028-001 AI/ML Description
      • R-TF-028-001 AI/ML Development Plan
      • R-TF-028-003 Data Collection Instructions - Prospective Data
      • R-TF-028-003 Data Collection Instructions - Retrospective Data
      • R-TF-028-004 Data Annotation Instructions - Visual Signs
      • R-TF-028-004 Data Annotation Instructions - Binary Indicator Mapping
      • R-TF-028-004 AI/ML Development Report
      • R-TF-028 AI/ML Release Report
      • R-TF-028 AI/ML Design Checks
    • Clinical
    • Cybersecurity
    • Design and development
    • Design History File
    • IFU and label
    • Post-Market Surveillance
    • Quality control
    • Risk Management
    • Usability and Human Factors Engineering
  • Legit.Health Plus Version 1.1.0.1
  • Licenses and accreditations
  • Applicable Standards and Regulations
  • Public tenders
  • Legit.Health Plus Version 1.1.0.0
  • Artificial Intelligence
  • R-TF-028 AI/ML Design Checks

R-TF-028 AI/ML Design Checks

Table of contents
  • Purpose
  • Instructions
    • Checklist
      • R-TF-028-001 AI/ML Description
      • R-TF-028-002 AI/ML Development Plan
      • Data Collection Instructions (R-TF-028-003, R-TF-028-004)
      • Data Annotation Instructions (R-TF-028-004, R-TF-028-005)
      • *R-TF-028-011 AI/ML Risk Matrix
    • Conclusion
    • Verification

Purpose​

This checklist is used to verify that the Design Phase of the AI/ML development lifecycle has been completed in accordance with procedure GP-028 AI Development. It ensures that the AI/ML Description, Development Plan, Data Collection Instructions, Data Annotation Instructions, and initial Risk Matrix are complete, coherent, and provide a sufficient basis for proceeding to the Development Phase.

Instructions​

The verifier must assess each item in the checklist. For each item, select "Yes," "No," or "N/A" and provide comments where necessary, especially for any "No" answers. All "No" items must be resolved before the Design Phase can be considered complete and approved.

Checklist​

R-TF-028-001 AI/ML Description​

Check ItemYes/No/NAComments
1. Is the purpose of the algorithm package clearly defined?
2. Is the ICD Category Distribution algorithm's function (ViT model, probability output) described?
3. Is the Binary Indicators' derivation logic (summation via matrix) clearly described?
4. Are the performance endpoints and success criteria for Top-k Accuracy (≥55%, ≥70%, ≥80%) explicitly stated?
5. Are the performance endpoints and success criteria for Binary Indicator AUC (≥0.80) explicitly stated?
6. Are the overall data specifications (scale, diversity, expert annotation) defined?
7. Are cybersecurity, transparency, and integration aspects sufficiently described?

R-TF-028-002 AI/ML Development Plan​

Check ItemYes/No/NAComments
1. Is the project team and their responsibilities clearly defined?
2. Is the development environment (hardware, software, tools) specified?
3. Does the Data Management Plan cover data collection, curation, partitioning, and test set sequestration?
4. Does the Training & Evaluation Plan cover model architecture, training methodology, and post-processing (e.g., calibration, TTA)?
5. Does the Release Plan specify the deliverables for the software integration team?
6. Does the plan include a comprehensive AI/ML Risk Management Plan?

Data Collection Instructions (R-TF-028-003, R-TF-028-004)​

Check ItemYes/No/NAComments
1. Are there clear and distinct instructions for retrospective data collection from public sources (R-TF-028-003)?
2. Are there clear and distinct instructions for prospective data collection from the clinical study (R-TF-028-004)?
3. For both, are the target population, inclusion/exclusion criteria, and ethical considerations (GDPR, consent) defined?
4. Are the technical protocols for data retrieval, de-identification, and transfer clearly specified?

Data Annotation Instructions (R-TF-028-004, R-TF-028-005)​

Check ItemYes/No/NAComments
1. Is the protocol for creating the Binary Indicator Mapping Matrix clear and unambiguous (R-TF-028-004)?
2. Are there clear instructions for annotating Visual Signs (R-TF-028-005), covering intensity, count (bounding boxes), and extent (polygons)?
3. Are the qualifications for the medical expert annotators clearly specified?
4. Is the Quality Control process, including the use of multiple annotators and a consensus mechanism, well-defined for each task?

*R-TF-028-011 AI/ML Risk Matrix​

Check ItemYes/No/NAComments
1. Have initial AI/ML risks related to data management (e.g., data bias, inaccurate labels) been identified?
2. Have initial AI/ML risks related to model training and evaluation (e.g., overfitting) been identified?
3. Has an initial assessment of severity and likelihood been performed for the identified risks?

Conclusion​

State the overall outcome of the design check.

☐ Design Phase Approved: All checks have been successfully passed. The project is cleared to proceed to the Development Phase.

☐ Design Phase Not Approved: One or more checks have failed. The responsible team members must address the comments and resubmit the design documentation for verification.

Overall Comments: Provide any summary comments or required actions here.

Verification​

Signature meaning

The signatures for the approval process of this document can be found in the verified commits at the repository for the QMS. As a reference, the team members who are expected to participate in this document and their roles in the approval process, as defined in Annex I Responsibility Matrix of the GP-001, are:

  • Author: Team members involved
  • Reviewer: JD-003, JD-004
  • Approver: JD-001
Previous
R-TF-028 AI/ML Release Report
Next
Clinical
  • Purpose
  • Instructions
    • Checklist
      • R-TF-028-001 AI/ML Description
      • R-TF-028-002 AI/ML Development Plan
      • Data Collection Instructions (R-TF-028-003, R-TF-028-004)
      • Data Annotation Instructions (R-TF-028-004, R-TF-028-005)
      • *R-TF-028-011 AI/ML Risk Matrix
    • Conclusion
    • Verification
All the information contained in this QMS is confidential. The recipient agrees not to transmit or reproduce the information, neither by himself nor by third parties, through whichever means, without obtaining the prior written permission of Legit.Health (AI LABS GROUP S.L.)